Updates are available Correction dated 2024-12-03
Click to view Correction: https://doi.org/10.1038/s41409-024-02469-y
-
Authors
McGuirk, Joseph P. https://orcid.org/0000-0002-0539-4796
Metheny, Leland III https://orcid.org/0000-0002-1980-9999
Pineiro, Luis
Litzow, Mark https://orcid.org/0000-0002-9816-6302
Rowley, Scott D. https://orcid.org/0000-0002-3299-835X
Avni, Batia
Tamari, Roni https://orcid.org/0000-0002-2386-0850
Lazarus, Hillard M. https://orcid.org/0000-0002-1159-5607
Rowe, Jacob M.
Sheleg, Michal
Rothenstein, Daniel
Halevy, Nitsan
Zuckerman, Tsila https://orcid.org/0000-0002-6204-977X
-
Funding
Funding for this research was provided by:
Pluri Biotech, Ltd.
Pluri-Biotch Ltd.
Pluri-Biotech, Ltd.
Pluri Biotech Ltd.
- License Information
-
More Information
Article History
Received: 17 February 2023
Revised: 12 July 2023
Accepted: 21 July 2023
First Online: 8 August 2023
Change Date: 18 November 2024
Change Type: Update
Change Details: The original online version of this article was revised: Following the publication of this article, the authors noted the omission of ‘et al’ in reference 16. The authors would also like to add an additional reference as below to add context on the original discovery of PLX-R18’s proposed therapeutic capabilities.
Change Date: 3 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-024-02469-y
Competing interests
: JPM has declared the following competing interests: Kite, Novartis, Bristol Myers Squibb, Allovir, Nektar, Sana, CRISPR (Ad Boards and consulting). LM has declared the following competing interests: Incyte (promotional speaker). LP has no competing interests. ML has declared the following competing interests: clinical trial finding (Abbvie, Amgen, Astellas, Novartis, Syndax, Actinium, Pluri-Biotech); advisory board (Jazz Pharmaceuticals); data monitoring board (BioSight). SDR has declared the following competing interests: SIRPant Immunotherapeutics (community advisory board), Realta Life Sciences (consultant). BA has no competing financial interests. RT has no competing financial interests. HML has declared the following competing interests: Actinium pharmaceuticals, Inc (consultant); Partner Therapeutics (consultant and stock options); Jazz Pharmaceuticals (speaker bureau and consultant); Pluri-Biotech, Inc.(consultant); Bristol-Myers Squibb (data safety monitoring board); Seattle Genetics (consultant and promotional speaker); AstraZeneca (promotional speaker); BioSight (data safety monitoring board); CSL Behring (consultant). JMR has declared the following competing interests: BioSight (consultant); Pluri-Biotech, Inc. (consultant). TZ has received honoraria from AbbVie, Orgenesis Inc, BioSight Ltd, Cellect Biotechnology, Janssen, Novartis and Gilead Sciences for participating in an advisory board or speaker’s bureau. MS, DR and NH are current employees of Pluri-Biotech.
